English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/40958
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorSoria Escoms, Bernat-
dc.contributor.authorBedoya Bergua, Francisco Javier-
dc.contributor.authorTejedo Huamán, Juan Rigoberto-
dc.contributor.authorHmadcha, Abdelkrim-
dc.contributor.authorRuiz-Salmerón, Rafael-
dc.contributor.authorLim, S.-
dc.contributor.authorMartín, Franz-
dc.identifier.citationCells Tissues Organs 188(1-2): 70-77 (2008)es_ES
dc.description8 páginas, 2 figuras, 3 tablas.es_ES
dc.description.abstractDiabetes is a chronic disease characterized by a deficit in β cell mass and a failure of glucose homeostasis. Both circumstances result in a variety of severe complications and an overall shortened life expectancy. Thus, diabetes represents an attractive candidate for cell therapy. Reversal of diabetes can be achieved through pancreas and islet transplantation, but shortage of donor organs has prompted an intensive search for alternative sources of β cells. This achievement has stimulated the search for appropriate stem cell sources. Both embryonic and adult stem cells have been used to generate surrogate β cells or otherwise restore β cell functioning. In this regard, several studies have reported the generation of insulin-secreting cells from embryonic and adult stem cells that normalized blood glucose values when transplanted into diabetic animal models. Due to β cell complexity, insulin-producing cells generated from stem cells do not possess all β cell attributes. This indicates the need for further development of methods for differentiation and selection of completely functional β cells. While these problems are overcome, diabetic patients may benefit from therapeutic strategies based on autologous stem cell therapies addressing late diabetic complications. In this article, we discuss the recent progress in the generation of insulin-producing cells from embryonic and adult stem cells, together with the challenges for the clinical use of diabetes stem cell therapy.es_ES
dc.description.sponsorshipThis study was supported in part by grants from Instituto de Salud Carlos III (TERCEL RD06/0010/0025, REDIMET RD06/0015/0013), MEC (SAF2006 06673, SAF2006-13686), Junta de Andalucía (CTS 576) and Fundación Progreso y Salud (FPS/0009/06).es_ES
dc.publisherS. Karger AGes_ES
dc.subjectDiabetes mellituses_ES
dc.subjectβ cellses_ES
dc.subjectEmbryonic stem cellses_ES
dc.titleCell Therapy for Diabetes Mellitus: An Opportunity for Stem Cells?es_ES
dc.description.peerreviewedPeer reviewedes_ES
Appears in Collections:(CABIMER) Artículos
Files in This Item:
There are no files associated with this item.
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.